Rifabutin
ریفابوتین
🦠 Antiinfectives For Systemic UseRifamycin
Market / country: 🇺🇸 USA
Mycobutin (US)
🧮 Dose calculator
Disseminated Mycobacterium avium complex (MAC) in HIV · Regimen source: FDA Rifabutin · Dosage and Administration
- • If nausea: 150 mg twice daily with food. Never alone in active TB (resistance). With lopinavir/ritonavir reduce by at least 75%. FDA Rifabutin · Dosage and AdministrationFDA Rifabutin · WarningsFDA Rifabutin · Precautions
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to rifabutin or other rifamycins; cabotegravir/rilpivirine injectable. FDA Rifabutin · Contraindications
Warnings
- • Must not be used for MAC prophylaxis in active TB; C. difficile diarrhoea; discoloured urine and tears; uveitis. FDA Rifabutin · Warnings
Renal adjustment
- • eGFR < 30: CrCl <30: consider reducing the dose by 50%. FDA Rifabutin · Dosage and Administration
Formulations
- 150 mg capsule — capsule 🇺🇸 USA FDA Rifabutin · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Rifabutin · PREGNANCY
“Rifabutin should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Rifabutin · NURSING MOTHERS
“Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Rifabutin · PEDIATRIC USE
“Safety and effectiveness of rifabutin for prophylaxis of MAC in children have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Rifabutin · GERIATRIC USE
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see CLINICAL PHARMACOLOGY ).”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA215041
- DailyMed (FDA label)FDA Rifabutin
- MedlinePlus (NIH)Rifabutin
- WHO ATC/DDDJ04AB04
- Darooyab (Iran)Rifabutin
🇮🇷 Registered in Iran Darooyab · G-491/Rifabutin
Dosage forms with Iranian generic codes, per Darooyab.
- 03016 · RIFABUTIN 150MG CAP · کپسول ریفابوتین ۱۵۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Rifabutin · How SuppliedFDA Rifabutin · Dosage and AdministrationFDA Rifabutin · WarningsFDA Rifabutin · PrecautionsFDA Rifabutin · ContraindicationsFDA Rifabutin · SPL approval / marketing categoryFDA Rifabutin · PREGNANCYFDA Rifabutin · NURSING MOTHERSFDA Rifabutin · PEDIATRIC USEFDA Rifabutin · GERIATRIC USE
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-491/Rifabutin
- Clinical review⚠ Unverified